antibody - List of Manufacturers, Suppliers, Companies and Products

antibody Product List

1～4 item / All 4 items

Displayed results
Tohoku University Technology: Monoclonal antibody recognizing phenyl sulfate: T16-063

Tohoku University Technology: Monoclonal antibody recognizing phenyl sulfate: T16-063

Able to simply diagnose diabetic nephropathy!

Phenyl sulfate (PS) is known to be a renal disease marker. After its ingestion, phenol is produced from tyrosine due to the intestinal bacteria action and it is absorbed in the intestines, then metabolized to PS in the liver. For healthy individuals, PS is excreted from the body as urine, but when kidney function is impaired, PS is not excreted and accumulates in the body. 　So far, PS detection was done using LC-MS or TOFMS equipment so the conventional method was not done simply. The inventor succeeded to product an antibody against PS. Using this antibody, it may be possible to easily detect PS, such as by ELISA method.

  • others

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
Tohoku University Technology: Diagnostic Method for Primary Aldosteronism: T12-182

Tohoku University Technology: Diagnostic Method for Primary Aldosteronism: T12-182

Adrenal venous blood samples accurately distinguish between tumor and non-tumor using HSD3B2 antibodies.

Primary aldosteronism is a condition characterized by the autonomous overproduction of steroids from the adrenal glands, and salt-sensitive primary aldosteronism is a disease that causes salt-sensitive hypertension due to this autonomous steroid overproduction. There are two pathological conditions: tumor-related (APA) and non-tumor-related (IHA), and since the treatment methods differ, differential diagnosis is important (APA requires adrenalectomy, while IHA is treated with medication). Until now, no markers have been found to distinguish between APA and IHA, making differentiation difficult, as morphological differences were used as criteria during definitive diagnosis based on pathological specimens. The inventors elucidated the 3βHSD-related steroid metabolic pathways in normal adrenal glands, IHA, and APA, and developed an evaluation method using the ratios as indicators in adrenal venous blood samples. Additionally, they established a monoclonal antibody specific to HSD3B2, which is abundant in APA, and achieved the differentiation of the pathological conditions of APA and IHA through immunostaining by using it in combination with HSD3B1 antibody.

  • others

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
Tohoku Univ. Technology：Method for predicting of sensitivity to chemotherapy for colorectal cancer: T14-026

Tohoku Univ. Technology：Method for predicting of sensitivity to chemotherapy for colorectal cancer: T14-026

Capable of selecting anti EGFR antibody-sensitive/resistant patient from Ras wild-type group

Anti-EGFR treatment for colorectal cancer is effective for patients without RAS mutation. However, response rate of the treatment is no more than 30%. This inventor analyzed the DNA methylation status of tissue samples from patients treated by anti-EGFR antibody. The result showed that highly methylated colorectal cancer (HMCC) has higher drug resistance than low methylated colorectal cancer (LMCC).

  • others

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration
Tohoku University Technology: Anti-Human LILRB4 Monoclonal Antibody：T20-3061

Tohoku University Technology: Anti-Human LILRB4 Monoclonal Antibody：T20-3061

As a new immune checkpoint inhibitor, it is a treatment for cancer, autoimmune diseases, and Alzheimer's disease.

The present invention relates to a novel anti-human B4 monoclonal antibody that specifically binds to the human immune inhibitory receptor LILRB4 (leukocyte immunoglobulin-like receptor B4) and inhibits its binding to its physiological ligand, fibronectin (FN). Key points of the present invention: - Novel immune checkpoint inhibitor: The B4-FN pathway is involved in the expression of immune suppressive functions mediated by B4, so an immune checkpoint inhibitor with this antibody as an active ingredient provides a new option for cancer immunotherapy. - Broad applicability to various diseases: It is expected to be utilized as a therapeutic agent for a wide range of immune checkpoint-related diseases involving B4, such as cancer, autoimmune diseases, inflammatory diseases, allergic diseases, and Alzheimer's disease.

  • others

Added to bookmarks

Bookmarks list

Bookmark has been removed

Bookmarks list

You can't add any more bookmarks

By registering as a member, you can increase the number of bookmarks you can save and organize them with labels.

Free membership registration

Search Keywords Related to antibody

COPYRIGHT © 2001-2026 IPROS CORPORATION ALL RIGHTS RESERVED.